drugset / Trial / NCT02034474
Tocilizumab as Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of Schizophrenia
Phase 4
Completed
59 enrolled
New York State Psychiatric Institute
Stanley Medical Research Institute · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
Randomized, double-blind clinical trial of tocilizumab vs. placebo as add-on treatment for residual positive, negative, and cognitive symptoms in schizophrenia. The primary study hypothesis is that individuals receiving tocilizumab will show greater improvements in their PANSS total scores than those taking placebo.
Timeline
- Start
- 2014-02
- Primary completion
- 2017-02-06
- Completion
- 2017-02-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tocilizumab | Monoclonal antibody | 8 mg/kg | Intravenous |